Luciano J. Costa MD PhD; IMS 2026: Teclistamab plus Daratumumab in Patients with Relapsed or Refractory Multiple Myeloma brings “Dramatic Reduction” of Progression Risk, Without Increased Risk of Death: MajesTEC-3 Phase Three Study Findings

Luciano J. Costa MD PhD; IMS 2026: Teclistamab plus Daratumumab in Patients with Relapsed or Refractory Multiple Myeloma brings “Dramatic Reduction” of Progression Risk, Without Increased Risk of Death: MajesTEC-3 Phase Three Study Findings

Luciano J. Costa MD PhD, Professor of Medicine, Director of the Multiple Myeloma Research and Treatment Program, University of Alabama, Birmingham, USA.
International Myeloma Society Annual Meeting, Glasgow, 2026
7:50

GLASGOW, Scotland—A combination of the bi-specific T-cell engager antibody teclistamab (that targets both B-cell maturation antigen and CD-3) paired with the anti-CD-38 monoclonal antibody daratumumab markedly extended relapse-free survival, and improved overall survival among patients with relapsed or refractory multiple myeloma in comparison with standard of care triplet therapy. This was in the international multi-center phase three MajesTEC-3 study reported at the 2026 Annual Meeting of the International Myeloma Society. Sarah Maxwell caught up with lead author Luciano Costa MD PhD, Professor of Medicine and Director of the Multiple Myeloma Research and Treatment Program at the University of Alabama, in Birmingham, USA.

Teclistamab plus Daratumumab in Patients with Relapsed or Refractory Multiple Myeloma brings “Dramatic Reduction” of Progression Risk, Without Increased Risk of Death: MajesTEC-3 Phase Three Study Latest

An Interview with:

Luciano J. Costa MD PhD, Professor of Medicine, Director of the Multiple Myeloma Research and Treatment Program, University of Alabama, Birmingham, USA.

GLASGOW, Scotland—A combination of the bi-specific T-cell engager antibody teclistamab (that targets both B-cell maturation antigen and CD-3) paired with the anti-CD-38 monoclonal antibody daratumumab markedly extended relapse-free survival, and improved overall survival among patients with relapsed or refractory multiple myeloma in comparison with standard of care triplet therapy.

This was in the international multi-center phase three MajesTEC-3 study reported at the 2026 Annual Meeting of the International Myeloma Society.

Sarah Maxwell caught up with lead author Luciano Costa MD PhD, Professor of Medicine and Director of the Multiple Myeloma Research and Treatment Program at the University of Alabama, in Birmingham, USA.

AUDIO JOURNAL OF ONOLOGY;Luciano Costa MD PhD

IN: “Hello, I am reporting from…”

OUT: “and the audio journal of oncology, bye bye” 7:50 secs

IMS Abstract:

MajesTEC-3 Overall Survival, Progression and Non-Relapse Mortality With Teclistamab Plus Daratumumab (Tec-Dara) vs Dara-Based Triplets in Relapsed/Refractory Multiple Myeloma (RRMM): MajesTEC-3 Post Hoc Analysis

Author: Luciano Costa

Hashtags:

#Teclistamab #Majest-TEC3 #majestTec3

#LucianoCosta #RelapsedRefractoryMultipleMyeloma #MultipleMyeloma #Daratumumab #IMS20206 #23rdInternationalMyelomaSocietyMeeting #InternationalMyelomaSocietyMeeting #IMS ##InternationalMyelomaSocietyMeeting

PRIOR PUBLICATIONS:

New England Journal of Medicine, 2025:

https://www.nejm.org/doi/full/10.1056/NEJMoa2514663

Teclistamab plus Daratumumab in Relapsed or Refractory Multiple Myeloma

Journal of Clinical Oncology, 2022:

https://ascopubs.org/doi/10.1200/JCO.2022.40.16_suppl.TPS8072

MajesTEC-3: Randomized, phase 3 study of teclistamab plus daratumumab versus investigator’s choice of daratumumab, pomalidomide, and dexamethasone or daratumumab, bortezomib, and dexamethasone in patients with relapsed/refractory multiple myeloma.